Co-developed by NYU Langone and Dana-Farber, the Solavia platform integrates EHR workflows, decision support, and pathway tracking for APPs and PAs.
|Articles|May 13, 2011
Elizabeth Blasiak on the Hourly Rounding Program Results
Author(s)Elizabeth Blasiak, RN, MSN
Oncology Nurse Elizabeth Blasiak on the Results of the Hourly Rounding Program
Advertisement
Elizabeth Blasiak, RN, MSN, OCN®, Medical Oncology, Smilow Cancer Hospital at Yale New Haven Hospital, New Haven, CT, on the hourly rounding program results.
Advertisement
Related to this article
The FDA expands accelerated approval for sevabertinib to frontline HER2-mutant NSCLC, highlighting a need for vigilant nursing management of diarrhea.
FDA approves camizestrant for ESR1-mutated advanced breast cancer, tasking oncology nurses with guiding patients through ctDNA-based surveillance.
Dana Delaski, MSN, FNP-BC, shares insights on how once-daily ruxolitinib, self-injected rusfertide, and givinostat will transform PV clinic workflows.
The FDA has approved oral iberdomide (Zenbexus) for relapsed/refractory multiple myeloma, offering patients a highly potent, accessible therapy.
Oncology clinicians must actively champion NCCN guidelines as a critical pillar of breast cancer survivorship care,
With daraxonrasib approved for metastatic pancreatic cancer, Yolanda Justal, APRN, discusses essential nursing workflows for home-based care.
Beth Sandy, CRNP, of Penn Medicine explains how oncology nurses and pharmacists collaborate to manage financial toxicity and secure oral therapies.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated, ER-Positive, HER2-Negative Advanced Breast Cancer
2
Gynecologic Cancer Awareness: Dr. Teplinsky Discusses Nursing Roles
3
Recognizing and Evaluating Diarrhea in Metastatic Triple-Negative Breast Cancer
4
WCLC 2026: Oncology Nursing Takeaways on Supportive Care and APP-Led Models
5